Global Enoxaparin API Market
Global Enoxaparin API Market

Enoxaparin API Comprehensive Study by Type (Enoxaparin API Powder, Enoxaparin API Injection), Application (Hospitals, Clinics, Others), Target Disease (Deep Vein Thrombosis, Pulmonary Embolism), Sales Channel (Offline, Online) Players and Region - Global Market Outlook to 2026

Enoxaparin API Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Mar 2021 Edition 220 Pages 216 Tables & Figures
Sample Report Speak with Analyst Request Discount
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Enoxaparin API is a medicine active ingredient used as an anticoagulant medication with low molecular weight heparin. It is used to treat and prevent conditions like pulmonary embolism and deep vein thrombosis (DVT). This API is also used during pregnancy or in certain types of surgeries to avoid any complications. These are available in powder and injection types used in hospitals and clinics.This growth is primarily driven by Prevalence of Deep Vein Thrombosis and Pulmonary Embolism Related Health Problems and Rising Number of Surgery and Need for Preventing Any Complications.

Globally, a noticeable market trend is evident Increasing Consumption of Enoxaparin API Injection in the Treatment. Major Players, such as Rochem International (United States), Atabay (Turkey), Meitheal Pharmaceuticals (United States), Amphastar Pharmaceuticals (United States), Sanofi-Aventis (France), Venipharm (France), ROVI SA (Spain) and Hebei Changshan Biochemical Pharmaceutical Co. (China) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 19th March 2019, Amphastar Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) granted approval of its Abbreviated New Drug Application (“ANDA”) for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial (MDV). The company currently manufactures and distributes Enoxaparin Sodium Injection in prefilled syringe form and this approval of the Multiple Dose Vial allows the company to begin offering the full line of Enoxaparin products.
On 28th May 2020, Meitheal Pharmaceuticals, Inc. announced the launch of Enoxaparin Sodium Injection, USP, the generic equivalent of Lovenox, in the United States market. Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF), its majority shareholder.

Market Drivers
  • Prevalence of Deep Vein Thrombosis and Pulmonary Embolism Related Health Problems
  • Rising Number of Surgery and Need for Preventing Any Complications

Market Trend
  • Increasing Consumption of Enoxaparin API Injection in the Treatment

Restraints
  • Side Effect Related Risks with Enoxaparin API

Opportunities
Innovation and Advancement in the Pharmaceutical Industry and Surging Demand for Enoxaparin API from Developing Nations
Challenges
Price Fluctuations in the Production of Enoxaparin API

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
AMA Research & Media features not only specific market forecasts, but also include significant value-added commentary on:
Market Trends
Technological Trends and Innovations
Regulatory Trends & Policies
Market Maturity Indicators
Market Share Movements
Growth Drivers and Constraints
New Entrants into the Market & Entry/Exit Barriers
Consumer Demographics
Supporting Company Financial and Cash Flow Planning
Open Up New Markets
To Seize Powerful Market Opportunities
Key Decision in Planning and to Further Expand Market Share
Identify Key Business Segments, Market Proposition & Gap Analysis
Report Objectives / Segmentation Covered
By Type
  • Enoxaparin API Powder
  • Enoxaparin API Injection
By Application
  • Hospitals
  • Clinics
  • Others
By Target Disease
  • Deep Vein Thrombosis
  • Pulmonary Embolism

By Sales Channel
  • Offline
  • Online

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Deep Vein Thrombosis and Pulmonary Embolism Related Health Problems
      • 3.2.2. Rising Number of Surgery and Need for Preventing Any Complications
    • 3.3. Market Challenges
      • 3.3.1. Price Fluctuations in the Production of Enoxaparin API
    • 3.4. Market Trends
      • 3.4.1. Increasing Consumption of Enoxaparin API Injection in the Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Enoxaparin API, by Type, Application, Target Disease, Sales Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Enoxaparin API (Value)
      • 5.2.1. Global Enoxaparin API by: Type (Value)
        • 5.2.1.1. Enoxaparin API Powder
        • 5.2.1.2. Enoxaparin API Injection
      • 5.2.2. Global Enoxaparin API by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Enoxaparin API by: Target Disease (Value)
        • 5.2.3.1. Deep Vein Thrombosis
        • 5.2.3.2. Pulmonary Embolism
      • 5.2.4. Global Enoxaparin API by: Sales Channel (Value)
        • 5.2.4.1. Offline
        • 5.2.4.2. Online
      • 5.2.5. Global Enoxaparin API Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Enoxaparin API: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Rochem International (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Atabay (Turkey)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Meitheal Pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amphastar Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi-Aventis (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Venipharm (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ROVI SA (Spain)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hebei Changshan Biochemical Pharmaceutical Co. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Enoxaparin API Sale, by Type, Application, Target Disease, Sales Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Enoxaparin API (Value)
      • 7.2.1. Global Enoxaparin API by: Type (Value)
        • 7.2.1.1. Enoxaparin API Powder
        • 7.2.1.2. Enoxaparin API Injection
      • 7.2.2. Global Enoxaparin API by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Enoxaparin API by: Target Disease (Value)
        • 7.2.3.1. Deep Vein Thrombosis
        • 7.2.3.2. Pulmonary Embolism
      • 7.2.4. Global Enoxaparin API by: Sales Channel (Value)
        • 7.2.4.1. Offline
        • 7.2.4.2. Online
      • 7.2.5. Global Enoxaparin API Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Enoxaparin API: by Type(USD Million)
  • Table 2. Enoxaparin API Enoxaparin API Powder , by Region USD Million (2015-2020)
  • Table 3. Enoxaparin API Enoxaparin API Injection , by Region USD Million (2015-2020)
  • Table 4. Enoxaparin API: by Application(USD Million)
  • Table 5. Enoxaparin API Hospitals , by Region USD Million (2015-2020)
  • Table 6. Enoxaparin API Clinics , by Region USD Million (2015-2020)
  • Table 7. Enoxaparin API Others , by Region USD Million (2015-2020)
  • Table 8. Enoxaparin API: by Target Disease(USD Million)
  • Table 9. Enoxaparin API Deep Vein Thrombosis , by Region USD Million (2015-2020)
  • Table 10. Enoxaparin API Pulmonary Embolism , by Region USD Million (2015-2020)
  • Table 11. Enoxaparin API: by Sales Channel(USD Million)
  • Table 12. Enoxaparin API Offline , by Region USD Million (2015-2020)
  • Table 13. Enoxaparin API Online , by Region USD Million (2015-2020)
  • Table 14. South America Enoxaparin API, by Country USD Million (2015-2020)
  • Table 15. South America Enoxaparin API, by Type USD Million (2015-2020)
  • Table 16. South America Enoxaparin API, by Application USD Million (2015-2020)
  • Table 17. South America Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 18. South America Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 19. Brazil Enoxaparin API, by Type USD Million (2015-2020)
  • Table 20. Brazil Enoxaparin API, by Application USD Million (2015-2020)
  • Table 21. Brazil Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 22. Brazil Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 23. Argentina Enoxaparin API, by Type USD Million (2015-2020)
  • Table 24. Argentina Enoxaparin API, by Application USD Million (2015-2020)
  • Table 25. Argentina Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 26. Argentina Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 27. Rest of South America Enoxaparin API, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Enoxaparin API, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 30. Rest of South America Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 31. Asia Pacific Enoxaparin API, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Enoxaparin API, by Type USD Million (2015-2020)
  • Table 33. Asia Pacific Enoxaparin API, by Application USD Million (2015-2020)
  • Table 34. Asia Pacific Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 35. Asia Pacific Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 36. China Enoxaparin API, by Type USD Million (2015-2020)
  • Table 37. China Enoxaparin API, by Application USD Million (2015-2020)
  • Table 38. China Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 39. China Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 40. Japan Enoxaparin API, by Type USD Million (2015-2020)
  • Table 41. Japan Enoxaparin API, by Application USD Million (2015-2020)
  • Table 42. Japan Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 43. Japan Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 44. India Enoxaparin API, by Type USD Million (2015-2020)
  • Table 45. India Enoxaparin API, by Application USD Million (2015-2020)
  • Table 46. India Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 47. India Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 48. South Korea Enoxaparin API, by Type USD Million (2015-2020)
  • Table 49. South Korea Enoxaparin API, by Application USD Million (2015-2020)
  • Table 50. South Korea Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 51. South Korea Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 52. Taiwan Enoxaparin API, by Type USD Million (2015-2020)
  • Table 53. Taiwan Enoxaparin API, by Application USD Million (2015-2020)
  • Table 54. Taiwan Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 55. Taiwan Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 56. Australia Enoxaparin API, by Type USD Million (2015-2020)
  • Table 57. Australia Enoxaparin API, by Application USD Million (2015-2020)
  • Table 58. Australia Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 59. Australia Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Enoxaparin API, by Type USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Enoxaparin API, by Application USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 64. Europe Enoxaparin API, by Country USD Million (2015-2020)
  • Table 65. Europe Enoxaparin API, by Type USD Million (2015-2020)
  • Table 66. Europe Enoxaparin API, by Application USD Million (2015-2020)
  • Table 67. Europe Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 68. Europe Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 69. Germany Enoxaparin API, by Type USD Million (2015-2020)
  • Table 70. Germany Enoxaparin API, by Application USD Million (2015-2020)
  • Table 71. Germany Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 72. Germany Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 73. France Enoxaparin API, by Type USD Million (2015-2020)
  • Table 74. France Enoxaparin API, by Application USD Million (2015-2020)
  • Table 75. France Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 76. France Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 77. Italy Enoxaparin API, by Type USD Million (2015-2020)
  • Table 78. Italy Enoxaparin API, by Application USD Million (2015-2020)
  • Table 79. Italy Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 80. Italy Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 81. United Kingdom Enoxaparin API, by Type USD Million (2015-2020)
  • Table 82. United Kingdom Enoxaparin API, by Application USD Million (2015-2020)
  • Table 83. United Kingdom Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 84. United Kingdom Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 85. Netherlands Enoxaparin API, by Type USD Million (2015-2020)
  • Table 86. Netherlands Enoxaparin API, by Application USD Million (2015-2020)
  • Table 87. Netherlands Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 88. Netherlands Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 89. Rest of Europe Enoxaparin API, by Type USD Million (2015-2020)
  • Table 90. Rest of Europe Enoxaparin API, by Application USD Million (2015-2020)
  • Table 91. Rest of Europe Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 92. Rest of Europe Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 93. MEA Enoxaparin API, by Country USD Million (2015-2020)
  • Table 94. MEA Enoxaparin API, by Type USD Million (2015-2020)
  • Table 95. MEA Enoxaparin API, by Application USD Million (2015-2020)
  • Table 96. MEA Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 97. MEA Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 98. Middle East Enoxaparin API, by Type USD Million (2015-2020)
  • Table 99. Middle East Enoxaparin API, by Application USD Million (2015-2020)
  • Table 100. Middle East Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 101. Middle East Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 102. Africa Enoxaparin API, by Type USD Million (2015-2020)
  • Table 103. Africa Enoxaparin API, by Application USD Million (2015-2020)
  • Table 104. Africa Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 105. Africa Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 106. North America Enoxaparin API, by Country USD Million (2015-2020)
  • Table 107. North America Enoxaparin API, by Type USD Million (2015-2020)
  • Table 108. North America Enoxaparin API, by Application USD Million (2015-2020)
  • Table 109. North America Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 110. North America Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 111. United States Enoxaparin API, by Type USD Million (2015-2020)
  • Table 112. United States Enoxaparin API, by Application USD Million (2015-2020)
  • Table 113. United States Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 114. United States Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 115. Canada Enoxaparin API, by Type USD Million (2015-2020)
  • Table 116. Canada Enoxaparin API, by Application USD Million (2015-2020)
  • Table 117. Canada Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 118. Canada Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 119. Mexico Enoxaparin API, by Type USD Million (2015-2020)
  • Table 120. Mexico Enoxaparin API, by Application USD Million (2015-2020)
  • Table 121. Mexico Enoxaparin API, by Target Disease USD Million (2015-2020)
  • Table 122. Mexico Enoxaparin API, by Sales Channel USD Million (2015-2020)
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Enoxaparin API: by Type(USD Million)
  • Table 132. Enoxaparin API Enoxaparin API Powder , by Region USD Million (2021-2026)
  • Table 133. Enoxaparin API Enoxaparin API Injection , by Region USD Million (2021-2026)
  • Table 134. Enoxaparin API: by Application(USD Million)
  • Table 135. Enoxaparin API Hospitals , by Region USD Million (2021-2026)
  • Table 136. Enoxaparin API Clinics , by Region USD Million (2021-2026)
  • Table 137. Enoxaparin API Others , by Region USD Million (2021-2026)
  • Table 138. Enoxaparin API: by Target Disease(USD Million)
  • Table 139. Enoxaparin API Deep Vein Thrombosis , by Region USD Million (2021-2026)
  • Table 140. Enoxaparin API Pulmonary Embolism , by Region USD Million (2021-2026)
  • Table 141. Enoxaparin API: by Sales Channel(USD Million)
  • Table 142. Enoxaparin API Offline , by Region USD Million (2021-2026)
  • Table 143. Enoxaparin API Online , by Region USD Million (2021-2026)
  • Table 144. South America Enoxaparin API, by Country USD Million (2021-2026)
  • Table 145. South America Enoxaparin API, by Type USD Million (2021-2026)
  • Table 146. South America Enoxaparin API, by Application USD Million (2021-2026)
  • Table 147. South America Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 148. South America Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 149. Brazil Enoxaparin API, by Type USD Million (2021-2026)
  • Table 150. Brazil Enoxaparin API, by Application USD Million (2021-2026)
  • Table 151. Brazil Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 152. Brazil Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 153. Argentina Enoxaparin API, by Type USD Million (2021-2026)
  • Table 154. Argentina Enoxaparin API, by Application USD Million (2021-2026)
  • Table 155. Argentina Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 156. Argentina Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 157. Rest of South America Enoxaparin API, by Type USD Million (2021-2026)
  • Table 158. Rest of South America Enoxaparin API, by Application USD Million (2021-2026)
  • Table 159. Rest of South America Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 160. Rest of South America Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 161. Asia Pacific Enoxaparin API, by Country USD Million (2021-2026)
  • Table 162. Asia Pacific Enoxaparin API, by Type USD Million (2021-2026)
  • Table 163. Asia Pacific Enoxaparin API, by Application USD Million (2021-2026)
  • Table 164. Asia Pacific Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 165. Asia Pacific Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 166. China Enoxaparin API, by Type USD Million (2021-2026)
  • Table 167. China Enoxaparin API, by Application USD Million (2021-2026)
  • Table 168. China Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 169. China Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 170. Japan Enoxaparin API, by Type USD Million (2021-2026)
  • Table 171. Japan Enoxaparin API, by Application USD Million (2021-2026)
  • Table 172. Japan Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 173. Japan Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 174. India Enoxaparin API, by Type USD Million (2021-2026)
  • Table 175. India Enoxaparin API, by Application USD Million (2021-2026)
  • Table 176. India Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 177. India Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 178. South Korea Enoxaparin API, by Type USD Million (2021-2026)
  • Table 179. South Korea Enoxaparin API, by Application USD Million (2021-2026)
  • Table 180. South Korea Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 181. South Korea Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 182. Taiwan Enoxaparin API, by Type USD Million (2021-2026)
  • Table 183. Taiwan Enoxaparin API, by Application USD Million (2021-2026)
  • Table 184. Taiwan Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 185. Taiwan Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 186. Australia Enoxaparin API, by Type USD Million (2021-2026)
  • Table 187. Australia Enoxaparin API, by Application USD Million (2021-2026)
  • Table 188. Australia Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 189. Australia Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 190. Rest of Asia-Pacific Enoxaparin API, by Type USD Million (2021-2026)
  • Table 191. Rest of Asia-Pacific Enoxaparin API, by Application USD Million (2021-2026)
  • Table 192. Rest of Asia-Pacific Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 193. Rest of Asia-Pacific Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 194. Europe Enoxaparin API, by Country USD Million (2021-2026)
  • Table 195. Europe Enoxaparin API, by Type USD Million (2021-2026)
  • Table 196. Europe Enoxaparin API, by Application USD Million (2021-2026)
  • Table 197. Europe Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 198. Europe Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 199. Germany Enoxaparin API, by Type USD Million (2021-2026)
  • Table 200. Germany Enoxaparin API, by Application USD Million (2021-2026)
  • Table 201. Germany Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 202. Germany Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 203. France Enoxaparin API, by Type USD Million (2021-2026)
  • Table 204. France Enoxaparin API, by Application USD Million (2021-2026)
  • Table 205. France Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 206. France Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 207. Italy Enoxaparin API, by Type USD Million (2021-2026)
  • Table 208. Italy Enoxaparin API, by Application USD Million (2021-2026)
  • Table 209. Italy Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 210. Italy Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 211. United Kingdom Enoxaparin API, by Type USD Million (2021-2026)
  • Table 212. United Kingdom Enoxaparin API, by Application USD Million (2021-2026)
  • Table 213. United Kingdom Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 214. United Kingdom Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 215. Netherlands Enoxaparin API, by Type USD Million (2021-2026)
  • Table 216. Netherlands Enoxaparin API, by Application USD Million (2021-2026)
  • Table 217. Netherlands Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 218. Netherlands Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 219. Rest of Europe Enoxaparin API, by Type USD Million (2021-2026)
  • Table 220. Rest of Europe Enoxaparin API, by Application USD Million (2021-2026)
  • Table 221. Rest of Europe Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 222. Rest of Europe Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 223. MEA Enoxaparin API, by Country USD Million (2021-2026)
  • Table 224. MEA Enoxaparin API, by Type USD Million (2021-2026)
  • Table 225. MEA Enoxaparin API, by Application USD Million (2021-2026)
  • Table 226. MEA Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 227. MEA Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 228. Middle East Enoxaparin API, by Type USD Million (2021-2026)
  • Table 229. Middle East Enoxaparin API, by Application USD Million (2021-2026)
  • Table 230. Middle East Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 231. Middle East Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 232. Africa Enoxaparin API, by Type USD Million (2021-2026)
  • Table 233. Africa Enoxaparin API, by Application USD Million (2021-2026)
  • Table 234. Africa Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 235. Africa Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 236. North America Enoxaparin API, by Country USD Million (2021-2026)
  • Table 237. North America Enoxaparin API, by Type USD Million (2021-2026)
  • Table 238. North America Enoxaparin API, by Application USD Million (2021-2026)
  • Table 239. North America Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 240. North America Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 241. United States Enoxaparin API, by Type USD Million (2021-2026)
  • Table 242. United States Enoxaparin API, by Application USD Million (2021-2026)
  • Table 243. United States Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 244. United States Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 245. Canada Enoxaparin API, by Type USD Million (2021-2026)
  • Table 246. Canada Enoxaparin API, by Application USD Million (2021-2026)
  • Table 247. Canada Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 248. Canada Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 249. Mexico Enoxaparin API, by Type USD Million (2021-2026)
  • Table 250. Mexico Enoxaparin API, by Application USD Million (2021-2026)
  • Table 251. Mexico Enoxaparin API, by Target Disease USD Million (2021-2026)
  • Table 252. Mexico Enoxaparin API, by Sales Channel USD Million (2021-2026)
  • Table 253. Research Programs/Design for This Report
  • Table 254. Key Data Information from Secondary Sources
  • Table 255. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Enoxaparin API: by Type USD Million (2015-2020)
  • Figure 5. Global Enoxaparin API: by Application USD Million (2015-2020)
  • Figure 6. Global Enoxaparin API: by Target Disease USD Million (2015-2020)
  • Figure 7. Global Enoxaparin API: by Sales Channel USD Million (2015-2020)
  • Figure 8. South America Enoxaparin API Share (%), by Country
  • Figure 9. Asia Pacific Enoxaparin API Share (%), by Country
  • Figure 10. Europe Enoxaparin API Share (%), by Country
  • Figure 11. MEA Enoxaparin API Share (%), by Country
  • Figure 12. North America Enoxaparin API Share (%), by Country
  • Figure 13. Global Enoxaparin API share by Players 2020 (%)
  • Figure 14. Global Enoxaparin API share by Players (Top 3) 2020(%)
  • Figure 15. Global Enoxaparin API share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Rochem International (United States) Revenue, Net Income and Gross profit
  • Figure 18. Rochem International (United States) Revenue: by Geography 2020
  • Figure 19. Atabay (Turkey) Revenue, Net Income and Gross profit
  • Figure 20. Atabay (Turkey) Revenue: by Geography 2020
  • Figure 21. Meitheal Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 22. Meitheal Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 23. Amphastar Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 24. Amphastar Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 25. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi-Aventis (France) Revenue: by Geography 2020
  • Figure 27. Venipharm (France) Revenue, Net Income and Gross profit
  • Figure 28. Venipharm (France) Revenue: by Geography 2020
  • Figure 29. ROVI SA (Spain) Revenue, Net Income and Gross profit
  • Figure 30. ROVI SA (Spain) Revenue: by Geography 2020
  • Figure 31. Hebei Changshan Biochemical Pharmaceutical Co. (China) Revenue, Net Income and Gross profit
  • Figure 32. Hebei Changshan Biochemical Pharmaceutical Co. (China) Revenue: by Geography 2020
  • Figure 33. Global Enoxaparin API: by Type USD Million (2021-2026)
  • Figure 34. Global Enoxaparin API: by Application USD Million (2021-2026)
  • Figure 35. Global Enoxaparin API: by Target Disease USD Million (2021-2026)
  • Figure 36. Global Enoxaparin API: by Sales Channel USD Million (2021-2026)
  • Figure 37. South America Enoxaparin API Share (%), by Country
  • Figure 38. Asia Pacific Enoxaparin API Share (%), by Country
  • Figure 39. Europe Enoxaparin API Share (%), by Country
  • Figure 40. MEA Enoxaparin API Share (%), by Country
  • Figure 41. North America Enoxaparin API Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Rochem International (United States)
  • Atabay (Turkey)
  • Meitheal Pharmaceuticals (United States)
  • Amphastar Pharmaceuticals (United States)
  • Sanofi-Aventis (France)
  • Venipharm (France)
  • ROVI SA (Spain)
  • Hebei Changshan Biochemical Pharmaceutical Co. (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount
Slider
Slider
Slider
DOWNLOAD SAMPLE PDF

Speak with Analyst

Want to find out more about this report?

Get Free Consultation
Ask a Question!

Related Reports

Knee Hyaluronic Acid Injections Comprehensive Study by Acid (Euflexxa, Hyalgan, Orthovisc, Monovisc, Supartz, Other), Sales Channel (Direct, Indirect), Dosage (Single Shot, Three-Five Shots), Solutio...
Knee Hyaluronic Acid Injections Comprehensive Study by Acid (Euflexxa, Hyalgan, Orthovisc, Monovisc, Supartz, Other), Sales Channel (Direct, Indirect), Dosage (Single Shot, Three-Five Shots), Solutio...
$ 3800
MET Inhibitor Drugs Comprehensive Study by Type (C-Met Biological Inhibitors, Small Molecule C-Met Inhibitors, C-Met Antagonist Antibodies, HGF Antagonist Antibodies, Kringle Variant Antagonists), Di...
MET Inhibitor Drugs Comprehensive Study by Type (C-Met Biological Inhibitors, Small Molecule C-Met Inhibitors, C-Met Antagonist Antibodies, HGF Antagonist Antibodies, Kringle Variant Antagonists), Di...
$ 3800
Kennel Cough Treatment Comprehensive Study by Application (Mild Cases, Secondary Infection), Drug Type (Baytril, Doxycycline, Clavamox, Others), Route of Administration (Oral, Injectable, Intra-nasal...
Kennel Cough Treatment Comprehensive Study by Application (Mild Cases, Secondary Infection), Drug Type (Baytril, Doxycycline, Clavamox, Others), Route of Administration (Oral, Injectable, Intra-nasal...
$ 3800
Antiviral Drugs Treatment Comprehensive Study by Type (Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Immune System Modulators), Application (Hepatitis, HIV/AIDS, Herpes, I...
Antiviral Drugs Treatment Comprehensive Study by Type (Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Immune System Modulators), Application (Hepatitis, HIV/AIDS, Herpes, I...
$ 3500
Fish Free Omega 3 Comprehensive Study by Type (Alpha-Linolenic Acid (ALA), Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA)), Application (Dietary Supplements, Pharma and Personal, Animal Feed...
Fish Free Omega 3 Comprehensive Study by Type (Alpha-Linolenic Acid (ALA), Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA)), Application (Dietary Supplements, Pharma and Personal, Animal Feed...
$ 3800
Triamterene Tablets Comprehensive Study by Application (Hospital, Retail Pharmacies, Other), End Use (Metabolic or Respiratory Acidosis, Acute Myopia & Secondary Angle-Closure Glaucoma), Packaging (B...
Triamterene Tablets Comprehensive Study by Application (Hospital, Retail Pharmacies, Other), End Use (Metabolic or Respiratory Acidosis, Acute Myopia & Secondary Angle-Closure Glaucoma), Packaging (B...
$ 4000